NO309477B1 - Nye heterocykliske aminometylforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem - Google Patents
Nye heterocykliske aminometylforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem Download PDFInfo
- Publication number
- NO309477B1 NO309477B1 NO975121A NO975121A NO309477B1 NO 309477 B1 NO309477 B1 NO 309477B1 NO 975121 A NO975121 A NO 975121A NO 975121 A NO975121 A NO 975121A NO 309477 B1 NO309477 B1 NO 309477B1
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- formula
- pharmaceutically acceptable
- compound
- piperazinyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 25
- 238000000034 method Methods 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- 239000002253 acid Substances 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 41
- -1 3-benzisothiazolyl group Chemical group 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- BXQNSPXDWSNUKE-UHFFFAOYSA-N 1,3-benzothiazole 1-oxide Chemical compound C1=CC=C2S(=O)C=NC2=C1 BXQNSPXDWSNUKE-UHFFFAOYSA-N 0.000 claims description 9
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- WCYSHOXQOUPHMZ-UHFFFAOYSA-N 3-methyl-1-oxo-2h-1,3-benzothiazole-6-carbaldehyde Chemical compound O=CC1=CC=C2N(C)CS(=O)C2=C1 WCYSHOXQOUPHMZ-UHFFFAOYSA-N 0.000 claims description 4
- NTKDDPUSWDZXKZ-UHFFFAOYSA-N 6-(hydroxymethyl)-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C(CO)C=C2OC(=O)N(C)C2=C1 NTKDDPUSWDZXKZ-UHFFFAOYSA-N 0.000 claims description 4
- NXBVOKQMQOBLFE-UHFFFAOYSA-N 6-(hydroxymethyl)-3h-1,3-benzoxazol-2-one Chemical compound OCC1=CC=C2NC(=O)OC2=C1 NXBVOKQMQOBLFE-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- JZDAXFQEVMZHNU-UHFFFAOYSA-N OCC1=CC2=C(N=CS2=O)C=C1 Chemical compound OCC1=CC2=C(N=CS2=O)C=C1 JZDAXFQEVMZHNU-UHFFFAOYSA-N 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000004312 hexamethylene tetramine Substances 0.000 claims description 4
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- JHTBBHZZWYRJEF-UHFFFAOYSA-N (3-methyl-1-oxo-2h-1,3-benzothiazol-6-yl)methanol Chemical compound OCC1=CC=C2N(C)CS(=O)C2=C1 JHTBBHZZWYRJEF-UHFFFAOYSA-N 0.000 claims description 3
- WQBBJFHMROHAEE-UHFFFAOYSA-N 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(OC3=CC(CN4CCN(CC4)C=4C(=CC=CC=4)F)=CC=C32)=O)CC1 WQBBJFHMROHAEE-UHFFFAOYSA-N 0.000 claims description 3
- VAGHMLAWINGTOD-UHFFFAOYSA-N 6-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)N(C)C2=CC=C1CN(CC1)CCN1C1=CC=C(Cl)C=C1 VAGHMLAWINGTOD-UHFFFAOYSA-N 0.000 claims description 3
- BRQGQZIOYURJGS-UHFFFAOYSA-N 7-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C=1C=C2N(C)C(=O)COC2=CC=1CN(CC1)CCN1C1=CC=CC=C1F BRQGQZIOYURJGS-UHFFFAOYSA-N 0.000 claims description 3
- QWQFYAJLVMKRLP-UHFFFAOYSA-N 7-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound COC1=CC=CC=C1N1CCN(CC=2C=C3OCC(=O)N(C)C3=CC=2)CC1 QWQFYAJLVMKRLP-UHFFFAOYSA-N 0.000 claims description 3
- UFRDLQXCPICZMV-UHFFFAOYSA-N 7-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C=1C=C2N(C)C(=O)COC2=CC=1CN(CC1)CCN1C1=CC=C(Cl)C=C1 UFRDLQXCPICZMV-UHFFFAOYSA-N 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 230000003920 cognitive function Effects 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- XCMKHSUEMSJMPT-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-[6-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-1-oxo-2h-1,3-benzothiazol-3-yl]ethyl]piperidin-4-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C3=CC=C(CN4CCN(CC4)C=4C(=CC=CC=4)F)C=C3S(=O)C2)CC1 XCMKHSUEMSJMPT-UHFFFAOYSA-N 0.000 claims description 2
- VTIPPXXXXXABFN-UHFFFAOYSA-N 4-[4-[(3-methyl-2-oxo-1,3-benzoxazol-6-yl)methyl]piperazin-1-yl]benzenesulfonamide Chemical compound C1=C2OC(=O)N(C)C2=CC=C1CN(CC1)CCN1C1=CC=C(S(N)(=O)=O)C=C1 VTIPPXXXXXABFN-UHFFFAOYSA-N 0.000 claims description 2
- ZHTQPUVZBKVMRI-UHFFFAOYSA-N 6-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]-3-methyl-2h-1,3-benzothiazole 1-oxide Chemical compound C1=CC=C2C(N3CCN(CC3)CC=3C=C4S(=O)CN(C4=CC=3)C)=NSC2=C1 ZHTQPUVZBKVMRI-UHFFFAOYSA-N 0.000 claims description 2
- ASZGPOHDTUREAC-UHFFFAOYSA-N 6-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)N(C)C2=CC=C1CN(CC1)CCN1C1=CC=CC=C1F ASZGPOHDTUREAC-UHFFFAOYSA-N 0.000 claims description 2
- IOSCLLIABRHSIJ-UHFFFAOYSA-N 6-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound COC1=CC=CC=C1N1CCN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 IOSCLLIABRHSIJ-UHFFFAOYSA-N 0.000 claims description 2
- AGXWBJHWQCWTQH-UHFFFAOYSA-N 6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound COC1=CC=CC(N2CCN(CC=3C=C4OC(=O)N(C)C4=CC=3)CC2)=C1 AGXWBJHWQCWTQH-UHFFFAOYSA-N 0.000 claims description 2
- VGMLLHAZGGNKJE-UHFFFAOYSA-N 6-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-3-methyl-2h-1,3-benzothiazole 1-oxide Chemical compound C=1C=C2N(C)CS(=O)C2=CC=1CN(CC1)CCN1C1=CC=C(Cl)C=C1 VGMLLHAZGGNKJE-UHFFFAOYSA-N 0.000 claims description 2
- IAAZLAZGZRKVRR-UHFFFAOYSA-N 6-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 IAAZLAZGZRKVRR-UHFFFAOYSA-N 0.000 claims description 2
- MGDVMVKEJXFDHP-UHFFFAOYSA-N 6-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-3-methyl-2h-1,3-benzothiazole 1-oxide Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3S(=O)CN(C)C3=CC=2)CC1 MGDVMVKEJXFDHP-UHFFFAOYSA-N 0.000 claims description 2
- SKINWCYULHXYOQ-UHFFFAOYSA-N 7-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound COC1=CC=CC(N2CCN(CC=3C=C4OCC(=O)N(C)C4=CC=3)CC2)=C1 SKINWCYULHXYOQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- WJMYOGZTSMOOOU-UHFFFAOYSA-N 4-[4-[(3-methyl-1-oxo-2h-1,3-benzothiazol-6-yl)methyl]piperazin-1-yl]benzenesulfonamide Chemical compound C=1C=C2N(C)CS(=O)C2=CC=1CN(CC1)CCN1C1=CC=C(S(N)(=O)=O)C=C1 WJMYOGZTSMOOOU-UHFFFAOYSA-N 0.000 claims 1
- CINUPGBOSVQIJE-UHFFFAOYSA-N 4-[4-[(4-methyl-3-oxo-1,4-benzoxazin-7-yl)methyl]piperazin-1-yl]benzenesulfonamide Chemical compound C=1C=C2N(C)C(=O)COC2=CC=1CN(CC1)CCN1C1=CC=C(S(N)(=O)=O)C=C1 CINUPGBOSVQIJE-UHFFFAOYSA-N 0.000 claims 1
- FKFUQQGHMQLCMO-UHFFFAOYSA-N 6-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC3=CC=C4N(C(OC4=C3)=O)C)=NSC2=C1 FKFUQQGHMQLCMO-UHFFFAOYSA-N 0.000 claims 1
- GNKXSSCIKCLIQB-UHFFFAOYSA-N 7-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC=3C=C4OCC(=O)N(C4=CC=3)C)=NSC2=C1 GNKXSSCIKCLIQB-UHFFFAOYSA-N 0.000 claims 1
- PKECYWZVWQZSLM-UHFFFAOYSA-N 7-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3OCC(=O)N(C)C3=CC=2)CC1 PKECYWZVWQZSLM-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003943 azolyl group Chemical group 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 78
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 54
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 54
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- 238000002844 melting Methods 0.000 description 40
- 230000008018 melting Effects 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 239000003480 eluent Substances 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 238000004566 IR spectroscopy Methods 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 229910021529 ammonia Inorganic materials 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 238000003760 magnetic stirring Methods 0.000 description 20
- 239000002244 precipitate Substances 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- BIFALRJCIAKLKQ-UHFFFAOYSA-N 6-(chloromethyl)-3-methyl-2h-1,3-benzothiazole 1-oxide Chemical compound ClCC1=CC=C2N(C)CS(=O)C2=C1 BIFALRJCIAKLKQ-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
- RPTVGPBAVWDIEM-UHFFFAOYSA-N 6-(chloromethyl)-3-methyl-1,3-benzoxazol-2-one Chemical compound C1=C(CCl)C=C2OC(=O)N(C)C2=C1 RPTVGPBAVWDIEM-UHFFFAOYSA-N 0.000 description 4
- 101150049660 DRD2 gene Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- IVTZRJKKXSKXKO-UHFFFAOYSA-N 1-(2-fluorophenyl)piperazine Chemical compound FC1=CC=CC=C1N1CCNCC1 IVTZRJKKXSKXKO-UHFFFAOYSA-N 0.000 description 3
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical group C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 3
- OULJRVTYLHHXBC-UHFFFAOYSA-N 6-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-3h-1,3-benzoxazol-2-one Chemical compound FC1=CC=CC=C1N1CCN(CC=2C=C3OC(=O)NC3=CC=2)CC1 OULJRVTYLHHXBC-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101150015707 HTR1A gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- PDBUTMYDZLUVCP-UHFFFAOYSA-N 3,4-dihydro-1,4-benzoxazin-2-one Chemical compound C1=CC=C2OC(=O)CNC2=C1 PDBUTMYDZLUVCP-UHFFFAOYSA-N 0.000 description 2
- QRMRRLXXFHXMBC-UHFFFAOYSA-N 3-methyl-1,3-benzoxazol-2-one Chemical compound C1=CC=C2OC(=O)N(C)C2=C1 QRMRRLXXFHXMBC-UHFFFAOYSA-N 0.000 description 2
- VNHQFRPZBXFNTO-UHFFFAOYSA-N 3-methyl-2-oxo-1,3-benzoxazole-6-carbaldehyde Chemical compound C1=C(C=O)C=C2OC(=O)N(C)C2=C1 VNHQFRPZBXFNTO-UHFFFAOYSA-N 0.000 description 2
- XSRCFFDUTPZZHD-UHFFFAOYSA-N 3-methyl-2h-1,3-benzothiazole 1-oxide Chemical compound C1=CC=C2N(C)CS(=O)C2=C1 XSRCFFDUTPZZHD-UHFFFAOYSA-N 0.000 description 2
- BEKCFMUSWXGPPG-UHFFFAOYSA-N 5-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]-2-(methylamino)phenol Chemical compound C1=C(O)C(NC)=CC=C1CN1CCN(C=2C3=CC=CC=C3SN=2)CC1 BEKCFMUSWXGPPG-UHFFFAOYSA-N 0.000 description 2
- SOZUCPFOSVOUMZ-UHFFFAOYSA-N 5-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2-(methylamino)phenol Chemical compound C1=C(O)C(NC)=CC=C1CN1CCN(C=2C(=CC=CC=2)OC)CC1 SOZUCPFOSVOUMZ-UHFFFAOYSA-N 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- JVIWOLLJSHIQDJ-UHFFFAOYSA-N 6-(chloromethyl)-1,3-benzothiazole 1-oxide Chemical compound ClCC1=CC2=C(N=CS2=O)C=C1 JVIWOLLJSHIQDJ-UHFFFAOYSA-N 0.000 description 2
- MYHPYPWWFFXQDY-UHFFFAOYSA-N 6-(chloromethyl)-3h-1,3-benzoxazol-2-one Chemical compound ClCC1=CC=C2NC(=O)OC2=C1 MYHPYPWWFFXQDY-UHFFFAOYSA-N 0.000 description 2
- JHWZXZFVUOMHQB-UHFFFAOYSA-N 6-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-1,3-benzothiazole 1-oxide Chemical compound FC1=C(C=CC=C1)N1CCN(CC1)CC1=CC2=C(N=CS2=O)C=C1 JHWZXZFVUOMHQB-UHFFFAOYSA-N 0.000 description 2
- YILOAHVWBVJOAK-UHFFFAOYSA-N 6-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1=C2OC(=O)N(C)C2=CC=C1CN(CC1)CCN1C1=CC=CC=C1F YILOAHVWBVJOAK-UHFFFAOYSA-N 0.000 description 2
- UXVMJPCQXADZAN-UHFFFAOYSA-N 6-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 UXVMJPCQXADZAN-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 2
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KRDOFMHJLWKXIU-UHFFFAOYSA-N ID11614 Chemical compound C1CNCCN1C1=NSC2=CC=CC=C12 KRDOFMHJLWKXIU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910003480 inorganic solid Inorganic materials 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical class [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229950001675 spiperone Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DDMVHGULHRJOEC-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazin-1-ium;chloride Chemical compound Cl.COC1=CC=CC=C1N1CCNCC1 DDMVHGULHRJOEC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IRCMYGHHKLLGHV-UHFFFAOYSA-N 2-ethoxy-3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl methanesulfonate Chemical compound C1=C(OS(C)(=O)=O)C=C2C(C)(C)C(OCC)OC2=C1 IRCMYGHHKLLGHV-UHFFFAOYSA-N 0.000 description 1
- LBIWDOXPCFPMPM-UHFFFAOYSA-N 3h-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2OC(=O)NC2=C1 LBIWDOXPCFPMPM-UHFFFAOYSA-N 0.000 description 1
- LZODAPKIQFPYIO-UHFFFAOYSA-N 4-(aminomethyl)-3h-1,3-benzoxazol-2-one Chemical compound NCC1=CC=CC2=C1NC(=O)O2 LZODAPKIQFPYIO-UHFFFAOYSA-N 0.000 description 1
- NXWDOFPAZKYMIS-UHFFFAOYSA-N 4-butyl-3h-1,3-benzoxazol-2-one Chemical compound CCCCC1=CC=CC2=C1NC(=O)O2 NXWDOFPAZKYMIS-UHFFFAOYSA-N 0.000 description 1
- QWLLYGDGABANLN-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C1=CC=C2NC(=O)COC2=C1 QWLLYGDGABANLN-UHFFFAOYSA-N 0.000 description 1
- UMXUIGVNIDRWED-UHFFFAOYSA-N 5-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-2-(methylamino)phenol Chemical compound C1=C(O)C(NC)=CC=C1CN1CCN(C=2C(=CC=CC=2)F)CC1 UMXUIGVNIDRWED-UHFFFAOYSA-N 0.000 description 1
- VAFVKRFDPSNZIJ-UHFFFAOYSA-N 6-(2-aminoethyl)-3h-1,3-benzoxazol-2-one Chemical class NCCC1=CC=C2NC(=O)OC2=C1 VAFVKRFDPSNZIJ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- MAGWMYAHYWHCBL-UHFFFAOYSA-N C(C)OC(=O)C1=CC2=C(N=CS2=O)C=C1 Chemical compound C(C)OC(=O)C1=CC2=C(N=CS2=O)C=C1 MAGWMYAHYWHCBL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- YXWHNMWKKMHTMV-UHFFFAOYSA-N Cl.C1=CC(OC)=CC=C1N1CCN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 Chemical compound Cl.C1=CC(OC)=CC=C1N1CCN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 YXWHNMWKKMHTMV-UHFFFAOYSA-N 0.000 description 1
- YBLBCDSEXNSBOK-UHFFFAOYSA-N Cl.CN1CS(C2=C1C=CC(=C2)CN2CCN(CC2)C2=C(C=CC=C2)OC)=O Chemical compound Cl.CN1CS(C2=C1C=CC(=C2)CN2CCN(CC2)C2=C(C=CC=C2)OC)=O YBLBCDSEXNSBOK-UHFFFAOYSA-N 0.000 description 1
- RDLAATHDACDCCR-UHFFFAOYSA-N Cl.CN1CS(C2=C1C=CC(=C2)CN2CCN(CC2)C2=CC=C(C=C2)OC)=O Chemical compound Cl.CN1CS(C2=C1C=CC(=C2)CN2CCN(CC2)C2=CC=C(C=C2)OC)=O RDLAATHDACDCCR-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UJQXEDGDZCOECV-UHFFFAOYSA-N [1-(2-chloroethyl)piperidin-4-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCCl)CC1 UJQXEDGDZCOECV-UHFFFAOYSA-N 0.000 description 1
- DQISATZECKFAAE-UHFFFAOYSA-N [1-(2-chloroethyl)piperidin-4-yl]-(4-fluorophenyl)methanone;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)C1CCN(CCCl)CC1 DQISATZECKFAAE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000003940 butylamines Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical class [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IGZWHQJAINSYBQ-UHFFFAOYSA-N ethyl 2-oxo-3h-1,3-benzoxazole-6-carboxylate Chemical compound CCOC(=O)C1=CC=C2NC(=O)OC2=C1 IGZWHQJAINSYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000012354 positive regulation of binding Effects 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9613652A FR2755690B1 (fr) | 1996-11-08 | 1996-11-08 | Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975121D0 NO975121D0 (no) | 1997-11-07 |
| NO975121L NO975121L (no) | 1998-05-11 |
| NO309477B1 true NO309477B1 (no) | 2001-02-05 |
Family
ID=9497457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO975121A NO309477B1 (no) | 1996-11-08 | 1997-11-07 | Nye heterocykliske aminometylforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5919784A (zh) |
| EP (1) | EP0841330B1 (zh) |
| JP (1) | JPH10139780A (zh) |
| CN (1) | CN1072655C (zh) |
| AT (1) | ATE202564T1 (zh) |
| AU (1) | AU726681B2 (zh) |
| BR (1) | BR9705456A (zh) |
| CA (1) | CA2220996A1 (zh) |
| DE (1) | DE69705376T2 (zh) |
| DK (1) | DK0841330T3 (zh) |
| ES (1) | ES2160308T3 (zh) |
| FR (1) | FR2755690B1 (zh) |
| GR (1) | GR3036472T3 (zh) |
| HK (1) | HK1010869A1 (zh) |
| HU (1) | HUP9701921A3 (zh) |
| NO (1) | NO309477B1 (zh) |
| NZ (1) | NZ329133A (zh) |
| PL (1) | PL323032A1 (zh) |
| PT (1) | PT841330E (zh) |
| ZA (1) | ZA9710055B (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177422B1 (en) | 1996-05-29 | 2001-01-23 | Warner-Lambert Company | Benzoxazinone dopamine D4 receptor antagonists |
| US6107313A (en) * | 1998-10-02 | 2000-08-22 | Combichem, Inc. | Dopamine receptor antagonists |
| FR2803298A1 (fr) * | 1999-12-30 | 2001-07-06 | Adir | Nouvelles urees lineaires ou cycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20040192669A1 (en) | 2000-04-13 | 2004-09-30 | Rosenfeld Mark J. | Novel compounds for use in weight loss and appetite suppression in humans |
| US7794761B2 (en) * | 2000-04-13 | 2010-09-14 | Seroctin Research & Technology, Inc. | Methods for inducing anti-anxiety and calming effects in animals and humans |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| UY28538A1 (es) * | 2003-09-26 | 2005-04-29 | Vertex Pharma | Derivados de fenil-piperazina como moduladores de receptores muscarínicos |
| US7524877B2 (en) | 2003-11-20 | 2009-04-28 | Seroctin Research & Technology, Inc. | Compounds for use in weight loss and appetite suppression in humans |
| DK2400968T3 (da) | 2009-02-26 | 2017-01-02 | Reviva Pharmaceuticals Inc | Sammensætninger, syntese og fremgangsmåder til anvendelse af arylpiperazinderivater |
| WO2011137046A1 (en) * | 2010-04-29 | 2011-11-03 | Merck Sharp & Dohme Corp. | Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2 |
| EP3371154A4 (en) * | 2015-10-30 | 2019-06-05 | Trillium Therapeutics Inc. | HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| FR2637286A1 (fr) * | 1988-10-04 | 1990-04-06 | Adir | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5234924A (en) * | 1990-09-26 | 1993-08-10 | Adir Et Compagnie | Benzothiazine and benzothiazole compounds useful as analgesics |
| FR2667068B1 (fr) * | 1990-09-26 | 1994-09-09 | Adir | Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| DE4037427A1 (de) * | 1990-11-24 | 1992-05-27 | Kali Chemie Pharma Gmbh | Heterocyclisch substituierte piperazinoalkylbenzoxazin und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| FR2674524B1 (fr) * | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2702214B1 (fr) * | 1993-03-05 | 1995-04-14 | Adir | Nouveaux composés (aryl(alkyl)carbonyl)-hétérocycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| FI951296A (fi) * | 1994-03-22 | 1995-09-23 | Adir | Uudet aminoalkyylibentsotiatsolinonit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset |
| FR2717810B1 (fr) * | 1994-03-22 | 1996-04-26 | Adir | Nouvelles aminoalkyl benzoxazolinones et benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
-
1996
- 1996-11-08 FR FR9613652A patent/FR2755690B1/fr not_active Expired - Fee Related
-
1997
- 1997-11-06 EP EP97402655A patent/EP0841330B1/fr not_active Expired - Lifetime
- 1997-11-06 DE DE69705376T patent/DE69705376T2/de not_active Expired - Fee Related
- 1997-11-06 DK DK97402655T patent/DK0841330T3/da active
- 1997-11-06 CA CA002220996A patent/CA2220996A1/fr not_active Abandoned
- 1997-11-06 AT AT97402655T patent/ATE202564T1/de not_active IP Right Cessation
- 1997-11-06 ES ES97402655T patent/ES2160308T3/es not_active Expired - Lifetime
- 1997-11-06 PT PT97402655T patent/PT841330E/pt unknown
- 1997-11-07 HU HU9701921A patent/HUP9701921A3/hu unknown
- 1997-11-07 CN CN97122237A patent/CN1072655C/zh not_active Expired - Fee Related
- 1997-11-07 ZA ZA9710055A patent/ZA9710055B/xx unknown
- 1997-11-07 US US08/966,040 patent/US5919784A/en not_active Expired - Fee Related
- 1997-11-07 AU AU44403/97A patent/AU726681B2/en not_active Ceased
- 1997-11-07 NZ NZ329133A patent/NZ329133A/en unknown
- 1997-11-07 NO NO975121A patent/NO309477B1/no not_active IP Right Cessation
- 1997-11-07 PL PL97323032A patent/PL323032A1/xx unknown
- 1997-11-10 JP JP9306849A patent/JPH10139780A/ja active Pending
- 1997-11-10 BR BR9705456-9A patent/BR9705456A/pt unknown
-
1998
- 1998-11-10 HK HK98111879A patent/HK1010869A1/xx not_active IP Right Cessation
-
2001
- 2001-08-30 GR GR20010401331T patent/GR3036472T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2755690B1 (fr) | 1998-12-18 |
| CN1182083A (zh) | 1998-05-20 |
| DE69705376D1 (de) | 2001-08-02 |
| DE69705376T2 (de) | 2002-02-14 |
| HUP9701921A3 (en) | 1999-03-29 |
| ES2160308T3 (es) | 2001-11-01 |
| EP0841330A1 (fr) | 1998-05-13 |
| NO975121D0 (no) | 1997-11-07 |
| NZ329133A (en) | 1998-08-26 |
| HK1010869A1 (en) | 1999-07-02 |
| EP0841330B1 (fr) | 2001-06-27 |
| CA2220996A1 (fr) | 1998-05-08 |
| FR2755690A1 (fr) | 1998-05-15 |
| PL323032A1 (en) | 1998-05-11 |
| DK0841330T3 (da) | 2001-09-03 |
| HUP9701921A2 (hu) | 1998-12-28 |
| ZA9710055B (en) | 1998-05-25 |
| ATE202564T1 (de) | 2001-07-15 |
| PT841330E (pt) | 2001-10-30 |
| CN1072655C (zh) | 2001-10-10 |
| AU726681B2 (en) | 2000-11-16 |
| JPH10139780A (ja) | 1998-05-26 |
| GR3036472T3 (en) | 2001-11-30 |
| HU9701921D0 (en) | 1998-01-28 |
| NO975121L (no) | 1998-05-11 |
| AU4440397A (en) | 1998-05-14 |
| BR9705456A (pt) | 2000-02-08 |
| US5919784A (en) | 1999-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040138230A1 (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
| US5296477A (en) | Aminoalkyl benzoxazine and benzthiazine compounds having a high 5-HT1A affinity | |
| BRPI0609785B1 (pt) | benzotiofenos substituídos por piperazina, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de benzotiofenos substituídos por piperazina ou um sal do mesmo, e, processo para produzir benzotiofenos substituídos por piperazina | |
| WO2008026046A1 (en) | Morpholine d3 dopamine antagonists | |
| NO309477B1 (no) | Nye heterocykliske aminometylforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem | |
| EP1131321B1 (en) | Indole derivatives and their use as serotonin receptor ligands | |
| US6391891B1 (en) | Bicyclic compounds as ligands for 5-HT1 receptors | |
| NO167916B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tiolaktam-n-eddiksyrederivater | |
| US8168634B2 (en) | Thiazole derivatives as kinase inhibitors | |
| SK282703B6 (sk) | Benzoxazinónový derivát, jeho použitie a farmaceutický prostriedok na jeho báze | |
| CA2035147A1 (en) | Thiazine (or oxazine) derivatives and preparation thereof | |
| CA2316388C (en) | Tetrahydrobenzindole derivative | |
| RU2489431C2 (ru) | Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2 | |
| IE913940A1 (en) | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents | |
| JPH05194441A (ja) | 新規な置換３−ピペラジニルアルキル−２，３−ジヒドロ−４ｈ−１，３−ベンゾオキサジン−４−オン、その製造法および治療用途 | |
| JP2705788B2 (ja) | 新規な、アミノアルキルベンゾオキサゾリノン及びベンゾチアゾリノン、それらの製造方法及びそれらを含有する製薬学的組成物 | |
| HU204517B (en) | Process for producing new 1,4-benzoxazine derivatives and pharmaceutical compositions containing them | |
| KR20010041341A (ko) | 벤질피페라지닐 및 벤질피페리디닐 에탄온 유도체, 이의제조 방법 및 도파민 ｄ４ 수용체 길항제로서의 이의 용도 | |
| MXPA05002003A (es) | Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia. | |
| CA3001649C (en) | Dopamine d3 receptor antagonists having a morpholine moiety | |
| US6521630B1 (en) | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | |
| JP2007513197A6 (ja) | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 | |
| JP2007513197A (ja) | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 | |
| JP2009538909A (ja) | ５‐ヒドロキシトリプタミン‐６リガンドとしてのベンゾオキサゾールおよびベンゾチアゾール誘導体 | |
| MXPA05003658A (es) | Derivados de piperazina sustituidos con oxindol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN MAY 2003 |